RxDoctor Payments Data

Chelsey Griffin, DO

Family Medicine · Tulsa, OKNPI 1437359288

Payments from drug & device makers

$8,162in general payments, 2019–2025

Across 617 payments — averaging $13.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$859
  • Novo Nordisk$563
  • AstraZeneca$544
  • Corium, LLC$362
  • Takeda Pharmaceuticals U.S.A., Inc.$353
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$8,157100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,162 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$48,134
Medicare patients
140
Services billed
831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$82,133
MounjaroTirzepatide41$49,440
JardianceEmpagliflozin34$45,633
JanuviaSitagliptin Phosphate18$30,206
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$29,055
RybelsusSemaglutide17$20,980
XareltoRivaroxaban13$19,199
NamzaricMemantine Hcl/Donepezil Hcl11$14,991
MyrbetriqMirabegron17$10,855
Tresiba Flextouch U-100Insulin Degludec22$9,905
PremarinEstrogens, Conjugated16$4,693
Omeprazole155$4,631
Breo ElliptaFluticasone/Vilanterol11$4,303
Atorvastatin Calcium192$3,018
Advair DiskusFluticasone Propion/Salmeterol13$2,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$563$103,11390 claims
Lilly USA, LLCMounjaro$275$49,44041 claims
Boehringer IngelheimJardiance$97$45,63334 claims
GSKTrelegy Ellipta, Breo Ellipta$213$33,35837 claims
MerckJanuvia$105$30,20618 claims
Johnson & JohnsonXarelto$203$19,19913 claims
AbbVieNamzaric, Synthroid$2,077$16,63226 claims
Astellas Pharma US IncMyrbetriq$197$10,85517 claims
PfizerPremarin$859$4,69316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →